Global Therapeutic Apheresis Market Set to Surge, Forecasted to Reach USD 5,264.4 Million by 2033

The global therapeutic apheresis market is set to experience remarkable growth, as highlighted in the latest forecast from Future Market Insights (FMI). Currently valued at USD 2,717.9 million in 2023, the market is expected to surge to USD 5,264.4 million by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 6.8% throughout the forecast period.

Therapeutic apheresis, a vital medical procedure used to separate and remove specific blood components, is witnessing an unprecedented increase in demand. This surge is attributed to several factors, including the rising prevalence of diseases requiring therapeutic intervention and a growing need for blood components.

Accelerate Your Success: Unlock the Secrets of the Therapeutic Apheresis Market the Sample Report

In addition to the rising demand, advancements in technology are playing a pivotal role in the development of innovative apheresis techniques. These technological advancements, coupled with favorable reimbursement policies and increased funding for apheresis procedures, are primary drivers propelling market growth.

The FMI report highlights that the convergence of these factors is creating a robust framework for the therapeutic apheresis market’s expansion. As the medical community continues to leverage these advancements, the market is well-positioned to meet the growing needs of patients and healthcare providers worldwide.

Key Takeaways:

• By 2033, the therapeutic apheresis industry in the United Kingdom is likely to expand, with a CAGR of 4.8%.
• In 2022, the United States developed the therapeutic apheresis business with a share of 28.8%.
• The therapeutic apheresis industry grew considerably to USD 2,577.9 million in 2022.
• The therapeutic apheresis sector expanded at a CAGR of 4.4% from 2018 to 2022.
• By 2033, China’s therapeutic apheresis industry is projected to develop with a CAGR of 8.3%.
• By 2033, India’s therapeutic apheresis industry is projected to expand with a CAGR of 6.8%.
• Japan’s therapeutic apheresis industry grew significantly, with a 4.2% share in 2022.
• Australia’s therapeutic apheresis industry is likely to expand with a CAGR of 6.1% by 2033.
• Germany’s therapeutic apheresis business grew, with a share of 6.3% in 2022.
• In 2022, based on the technology, centrifugation dominated the market, with a share of 58.3%.
• In 2022, the blood bank segment dominated the market, with a share of 43.5%, based on end users.

Transform Your Business Approach with the Intelligence from Our Full Report

Competitors Winning Strategies:

The market has currently demonstrated budding success and is well-established in several locations. As a result of growing government activities, more individuals are becoming aware of the industry under study, fueling its expansion. Strategic partnerships and new product launches by large corporations are also anticipated to fuel market expansion.

Recent Developments:

• The TORAYMYXIN medical device was introduced to the European market by Toray Medical Co. Ltd. (Japan) in June 2019.
• Baxter International Inc. (United States) introduced the PrisMax system in the US in July 2019.
• In June 2022, Terumo Blood and Cell Technologies announced that the automated red blood cell exchange procedure performed on the company’s Spectra Optia Apheresis System had been selected by the NHS MedTech Funding Mandate (MTFM) programme in NHS England in the United Kingdom to treat sickle cell disease.
• In July 2022, Eliaz Therapeutics and Terumo Blood and Cell Technologies worked together to create and market a breakthrough therapeutic apheresis therapy for acute renal damage (AKI).

Key Players:

• Asahi Kasei Medical Co.
• Haemonetics Corporation
• Miltenyi Biotec
• Cerus Corporation
• Terumo BCT Inc.
• Fresenius Kabi USA
• Terumo Bct
• B. Braun Melsungen AG
• Nikkiso Co. Ltd.
• Medica S.p.A.
• Baxter Healthcare Corporation
• Kawasumi Laboratories Inc.
• Therakos Incorporation

Key Segments:

By Procedure Types:

• Therapeutic Plasma Exchange (TPE)
• Red Blood Cell Exchange (RBCX)
• Cellular Depletions

By Technology:

• Centrifugation
• Membrane filtration

By Application:

• Hematology
• Neurology
• Nephrology
• Rheumatology
• Oncology
• Others

By End User:

• Hospitals
• Blood banks
• Specialty clinics

By Region:

• North America
• Latin America
• Asia Pacific
• MEA
• Europe

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube